Robot maker · registered
Noah Medical
Galaxy System uses Embedded Imaging Technology (EIT) for real-time tool-in-lesion visualization and adaptive AI-guided scope navigation; co-registers pre-operative CT with live bronchoscopic view; autonomous nodule targeting for pulmonary biopsy; 96.7% diagnostic yield reported in MATCH II Study; NVIDIA Isaac for Healthcare integration in development.
Company overview
Identity and operating footprint
Robot models
Specifications remain vendor-claimed
Galaxy System
- FDA cleared for robotic navigated bronchoscopy
vendor-stated US regulatory clearance for bronchoscopic visualization and access to patient airways
Claim source - 96.7% diagnostic yield (MATCH II Study, 31 patients)
vendor-cited clinical study result for pulmonary nodule biopsy
Claim source - 5,000+ procedures completed in the United States
vendor-stated cumulative US procedure count milestone as of March 2025
Claim source
Deployment log
Announced and cited only
Funding history
Publicly announced rounds
Series B
1955 Capital, AME Cloud Ventures, Aramco Ventures, Hillhouse Capital, Hillhouse Investment Group, HongShan, Lyfe Capital, Prosperity7 Ventures, Shangbay Capital, SoftBank Vision Fund, SoftBank Vision Fund 2, Summed Capital, Sunmed Capital, Tiger Global Management, Uphonest Capital
Round sourceHiring signal
Public job board · 2026-07-13
Hiring is an operating signal, not deployment evidence. Roles are refreshed from the company’s public careers system.
Company timeline
Milestones and announcements
Source ledger
12 unique public sources